000291412 001__ 291412
000291412 005__ 20241029141622.0
000291412 0247_ $$2doi$$a10.3390/cancers16122276
000291412 0247_ $$2pmid$$apmid:38927981
000291412 0247_ $$2pmc$$apmc:PMC11201711
000291412 037__ $$aDKFZ-2024-01386
000291412 041__ $$aEnglish
000291412 082__ $$a610
000291412 1001_ $$00000-0001-8119-9119$$aBisanzi, Simonetta$$b0
000291412 245__ $$aBaseline Cell-Free DNA Can Predict Malignancy of Nodules Observed in the ITALUNG Screening Trial.
000291412 260__ $$aBasel$$bMDPI$$c2024
000291412 3367_ $$2DRIVER$$aarticle
000291412 3367_ $$2DataCite$$aOutput Types/Journal article
000291412 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719836794_5815
000291412 3367_ $$2BibTeX$$aARTICLE
000291412 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291412 3367_ $$00$$2EndNote$$aJournal Article
000291412 500__ $$a#LA:C020#
000291412 520__ $$aThe role of total plasma cell-free DNA (cfDNA) in lung cancer (LC) screening with low-dose computed tomography (LDCT) is uncertain. We hypothesized that cfDNA could support differentiation between malignant and benign nodules observed in LDCT. The baseline cfDNA was measured in 137 subjects of the ITALUNG trial, including 29 subjects with screen-detected LC (17 prevalent and 12 incident) and 108 subjects with benign nodules. The predictive capability of baseline cfDNA to differentiate malignant and benign nodules was compared to that of Lung-RADS classification and Brock score at initial LDCT (iLDCT). Subjects with prevalent LC showed both well-discriminating radiological characteristics of the malignant nodule (16 of 17 were classified as Lung-RADS 4) and markedly increased cfDNA (mean 18.8 ng/mL). The mean diameters and Brock scores of malignant nodules at iLDCT in subjects who were diagnosed with incident LC were not different from those of benign nodules. However, 75% (9/12) of subjects with incident LC showed a baseline cfDNA ≥ 3.15 ng/mL, compared to 34% (37/108) of subjects with benign nodules (p = 0.006). Moreover, baseline cfDNA was correlated (p = 0.001) with tumor growth, measured with volume doubling time. In conclusion, increased baseline cfDNA may help to differentiate subjects with malignant and benign nodules at LDCT.
000291412 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000291412 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291412 650_7 $$2Other$$abiomarkers
000291412 650_7 $$2Other$$acell-free DNA
000291412 650_7 $$2Other$$alow-dose CT
000291412 650_7 $$2Other$$alung cancer
000291412 650_7 $$2Other$$aprediction
000291412 650_7 $$2Other$$ascreening
000291412 7001_ $$00000-0002-3820-4442$$aPuliti, Donella$$b1
000291412 7001_ $$aPicozzi, Giulia$$b2
000291412 7001_ $$aRomei, Chiara$$b3
000291412 7001_ $$00000-0001-5612-6364$$aPistelli, Francesco$$b4
000291412 7001_ $$aDeliperi, Annalisa$$b5
000291412 7001_ $$00000-0002-1427-637X$$aCarreras, Giulia$$b6
000291412 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b7
000291412 7001_ $$00000-0002-1413-5948$$aGorini, Giuseppe$$b8
000291412 7001_ $$aZappa, Marco$$b9
000291412 7001_ $$aSani, Cristina$$b10
000291412 7001_ $$aCarrozzi, Laura$$b11
000291412 7001_ $$aPaci, Eugenio$$b12
000291412 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b13$$udkfz
000291412 7001_ $$aCarozzi, Francesca Maria$$b14
000291412 7001_ $$0P:(DE-He78)eba11eff7c9c475da132d5343d569759$$aMascalchi, Mario$$b15$$eLast author
000291412 7001_ $$aGroup, ITALUNG Working$$b16$$eCollaboration Author
000291412 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers16122276$$gVol. 16, no. 12, p. 2276 -$$n12$$p2276$$tCancers$$v16$$x2072-6694$$y2024
000291412 8564_ $$uhttps://inrepo02.dkfz.de/record/291412/files/cancers-16-02276-v2.pdf
000291412 8564_ $$uhttps://inrepo02.dkfz.de/record/291412/files/cancers-16-02276-v2.pdf?subformat=pdfa$$xpdfa
000291412 909CO $$ooai:inrepo02.dkfz.de:291412$$pVDB
000291412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000291412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eba11eff7c9c475da132d5343d569759$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000291412 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000291412 9141_ $$y2024
000291412 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000291412 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000291412 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000291412 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000291412 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000291412 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000291412 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000291412 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000291412 980__ $$ajournal
000291412 980__ $$aVDB
000291412 980__ $$aI:(DE-He78)C020-20160331
000291412 980__ $$aUNRESTRICTED